
Pipeline
Indication
Combination Agent (Study Name)
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
Fast Track
Collaboration Partner
Evorpacept Combination Studies
CHECKPOINT
INHIBITORS
INHIBITORS
Indication:
HNSCC
(Head and Neck Squamous Cell Carcinoma)
HNSCC
Head and Neck Squamous Cell Carcinoma
Combination Agent (Study Name):
Keytruda (ASPEN-03)
Keytruda (ASPEN-03)
CHECKPOINT
INHIBITORS
INHIBITORS
Indication:
HNSCC
(Head and Neck Squamous Cell Carcinoma)
HNSCC
Head and Neck Squamous Cell Carcinoma
Combination Agent (Study Name):
Keytruda + 5FU + Platinum (ASPEN-04)
Keytruda + 5FU + Platinum (ASPEN-04)
ANTI-CANCER ANTIBODIES
AND ADCS
AND ADCS
Indication:
GC
(Gastric/Gastroesophageal Junction Cancer)
GC
Gastric/Gastroesophageal Junction Cancer
Combination Agent (Study Name):
Herceptin + Cyramza + Paclitaxel (ASPEN-06)
Herceptin + Cyramza + Paclitaxel (ASPEN-06)
ANTI-CANCER ANTIBODIES
AND ADCS
AND ADCS
Indication:
Urothelial Cancer
Urothelial Cancer
Combination Agent (Study Name):
Padcev (ASPEN-07)
Padcev (ASPEN-07)
ANTI-CANCER ANTIBODIES
AND ADCS
AND ADCS
Indication:
Breast Cancer
Breast Cancer
Combination Agent (Study Name):
Zanidatamab
Zanidatamab
ANTI-CANCER ANTIBODIES
AND ADCS
AND ADCS
Indication:
Breast Cancer
Breast Cancer
Combination Agent (Study Name):
Enhertu (I-SPY)
Enhertu (I-SPY)
ANTI-CANCER ANTIBODIES
AND ADCS
AND ADCS
Indication:
MM
(Multiple Myeloma)
MM
Multiple Myeloma
Combination Agent (Study Name):
Sarclisa + Dexamethasone
Sarclisa + Dexamethasone
ALTA-
002*
002*
Indication:
Advanced Cancer
Advanced Cancer
*SIRPα Toll-like receptor agonist antibody conjugate (TRAAC)
Clinical Trials
ALX Oncology Sponsored Trials
- A Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma (ASPEN-01)
- A Study of ALX148 with Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
- ALX148 in Combination with Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
- ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
- A Study of Evorpacept (ALX148) with Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
- A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)
- A Study of Evorpacept (ALX148) with Enfortumab Vedotin for Subjects with Urothelial Carcinoma (ASPEN-07)
Collaboration Partner Sponsored Trials
Investigator Sponsored Trials
- ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
- A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer